Tecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses.
Mitchell, P Thatcher, Nick Socinski, M Wasilewska-Tesluk, E Horwood, K Szczesna, A Martín, C Ragulin, Y Zukin, M Helwig, C
Mitchell, P
Thatcher, Nick
Socinski, M
Wasilewska-Tesluk, E
Horwood, K
Szczesna, A
Martín, C
Ragulin, Y
Zukin, M
Helwig, C
Citations
Altmetric:
Abstract
Tecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary endpoint but reported notable survival benefit with tecemotide versus placebo in an exploratory analysis of the predefined patient subgroup treated with concurrent chemoradiotherapy. Here, we attempted to gain further insight into the effects of tecemotide in START.
Description
Date
2015-02-26
Publisher
Collections
Keywords
Type
Article
Citation
Tecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses. 2015: Ann Oncol